Farmington, United States
ImStem Biotechnology is a biotechnology company founded in 2012, headquartered in the United States. The company focuses on developing cell therapeutic products derived from human pluripotent stem cells (hESC or iPSC) for tissue repair and the treatment of neural, heart, vascular, blood system diseases, and autoimmune diseases. Their state-of-the-art stem cell technologies enable them to provide various therapeutic and research products with an unlimited supply and consistent quality in the near future.
The company secured a significant $1.10 million grant investment on 06 October 2013. This funding injection underscores the confidence in ImStem's approach to utilizing stem cells for therapeutic purposes. Although the specific investors behind this grant investment are not disclosed, the financial support further propels ImStem's mission to advance regenerative medicine and address various medical conditions.
ImStem Biotechnology operates in the biotechnology and health care industries, positioning itself at the forefront of technological advancements to bring about innovative healthcare solutions and contribute to the evolving landscape of biotechnology.
